Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973369 | 0.92 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL10964227 | 0.88 | — | — | |
| SCHEMBL40453 | 0.88 | LMNA (0.42) | MAPK1LMNAALDH1A1TP53 | |
| SCHEMBL28469818 | 0.86 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL2119475 | 0.85 | ALDH1A1 (0.33) | MAPK1ALDH1A1 | |
| SCHEMBL29017806 | 0.85 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL755735 | 0.82 | — | — | |
| SCHEMBL975871 | 0.80 | — | — | |
| SCHEMBL27741937 | 0.78 | — | — | |
| SCHEMBL11577814 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | claimed |
| CN-104109235-A | Mono-functionalized polyethylene glycol with nitrogen atom branched center and its preparation method and biologically-relevant matter | XIAMEN SINOPEG BIOTECH CO LTD | 2014-10-22 | — | — | CN | claimed |
| EP-1979362-B1 | NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-12-15 | — | — | EP | claimed |
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-01-01 | — | — | US | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | disclosed |
| WO-1998049156-A1 | PROCESSES FOR PREPARING BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048787-A1 | INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998048793-A1 | INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0875510-A1 | Process for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875507-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0174680-B1 | SUBSTITUTED 4-FLUOROTHIOCARBANILIDE HERBICIDAL COMPOUNDS AND METHODS OF USE | STAUFFER CHEMICAL COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4399075-A | Process for producing chlorinated phenoxytoluene derivatives | ASAHI CHEMICAL COMPANY, LIMITED (JP) | 1983-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | MAPK1 639/4885LMNA 4541/4885ALDH1A1 3563/4885 |
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | SELE, ELANE, EPCAM | MAPK1 4013/4885LMNA 2091/4885ALDH1A1 374/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | MAPK1 4480/4885LMNA 4220/4885ALDH1A1 3280/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | MAPK1 4572/4885LMNA 4224/4885ALDH1A1 3787/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | MAPK1 4705/4885LMNA 4551/4885ALDH1A1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.